Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

by Cortes, J., Lipton, J.H., Rea, D., Digumarti, R., Chuah, C., Nanda, N., Benichou, A.-C., Craig, A.R., Michallet, M., Nicolini, F.E., Kantarjian, H.
Published 2016